G1 Therapeutics, Inc. (GTHX)
Sep 18, 2024 - GTHX was delisted (acquired by Pharmacosmos)
7.15
0.00 (0.00%)
Inactive · Last trade price
on Sep 17, 2024
G1 Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for G1 Therapeutics stock had an average target of 3.5, with a low estimate of 3 and a high estimate of 4.
Price Target: $3.5 (-51.05%)
Analyst Consensus: Buy
No price target forecast data available
* Price targets were last updated on Jun 25, 2024.
Analyst Ratings
The average analyst rating for G1 Therapeutics stock from 4 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $3 | Strong Buy | Maintains | $9 → $3 | -58.04% | Jun 25, 2024 |
| Needham | Needham | Strong Buy Maintains $12 → $6 | Strong Buy | Maintains | $12 → $6 | -16.08% | Jun 25, 2024 |
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +67.83% | Jun 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +25.87% | May 28, 2024 |
Financial Forecast
Revenue This Year
75.01M
from 82.51M
Decreased by -9.09%
Revenue Next Year
96.38M
from 75.01M
Increased by 28.49%
EPS This Year
-0.42
from -0.93
EPS Next Year
0.05
from -0.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 84.9M | 106.4M | 133.5M | ||
| Avg | 75.0M | 96.4M | 110.6M | ||
| Low | 67.6M | 82.3M | 87.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.9% | 41.8% | 38.5% | ||
| Avg | -9.1% | 28.5% | 14.7% | ||
| Low | -18.0% | 9.7% | -8.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.14 | 0.25 | 0.58 | ||
| Avg | -0.42 | 0.05 | 0.22 | ||
| Low | -0.58 | -0.03 | -0.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 978.4% | ||
| Avg | - | - | 319.0% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.